Cidofovir incorporation into human keratinocytes with episomal HPV 16 results in nonselective cytotoxicity

William C. Spanos, Mark El-Deiry, John H. Lee

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives: Recurrent respiratory papillomatosis (RRP) is caused by human papillomavirus (HPV). Surgical excision is the mainstay of treatment; however, medical therapy including cidofovir, a cytosine analog, has been investigated. Human papillomavirus does not encode a viral DNA polymerase, which is the known target of cidofovir in cytomegalovirus infections. Methods: In an effort to better understand the usefulness of cidofovir in the treatment of HPV-related disease, we tested cidofovir's ability to inhibit growth, alter gene expression, and inhibit genome replication. Results: With the use of carbon 14-labeled cidofovir in episomal HPV 16-containing keratinocytes, there was a minimal increase in cidofovir incorporation into episomal DNA versus genomic DNA. Cidofovir decreased the copies of episomal HPV 16 in keratinocytes; however, the copies per cell returned to baseline levels once cidofovir was removed. Expression of a viral oncogene (HPV 16 E6) in transformed keratinocytes with episomal HPV 16 was not decreased by cidofovir. Cytotoxicity in head and neck squamous cell carcinoma lines exposed to cidofovir correlated with cell doubling time, and not with HPV status. Also, tonsil keratinocytes transformed with episomal HPV 16 did not exhibit greater cidofovir-mediated toxicity than did telomerase-transformed keratinocytes. Conclusions: These findings suggest that any potential in vivo benefit of cidofovir therapy results from non-viral-specific cell toxicity at the site of application.

Original languageEnglish (US)
Pages (from-to)840-846
Number of pages7
JournalAnnals of Otology, Rhinology and Laryngology
Volume114
Issue number11
DOIs
StatePublished - Nov 2005

Fingerprint

Human papillomavirus 16
Keratinocytes
cidofovir
Telomerase
Palatine Tonsil
Cytosine
DNA
Viral DNA
Cytomegalovirus Infections
DNA-Directed DNA Polymerase
Oncogenes
Carbon
Genome

Keywords

  • Cytotoxicity
  • Human papillomavirus
  • Keratinocyte
  • Recurrent respiratory papillomatosis

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Cidofovir incorporation into human keratinocytes with episomal HPV 16 results in nonselective cytotoxicity. / Spanos, William C.; El-Deiry, Mark; Lee, John H.

In: Annals of Otology, Rhinology and Laryngology, Vol. 114, No. 11, 11.2005, p. 840-846.

Research output: Contribution to journalArticle

@article{91a909bbc4d240d6bead799e40d981a3,
title = "Cidofovir incorporation into human keratinocytes with episomal HPV 16 results in nonselective cytotoxicity",
abstract = "Objectives: Recurrent respiratory papillomatosis (RRP) is caused by human papillomavirus (HPV). Surgical excision is the mainstay of treatment; however, medical therapy including cidofovir, a cytosine analog, has been investigated. Human papillomavirus does not encode a viral DNA polymerase, which is the known target of cidofovir in cytomegalovirus infections. Methods: In an effort to better understand the usefulness of cidofovir in the treatment of HPV-related disease, we tested cidofovir's ability to inhibit growth, alter gene expression, and inhibit genome replication. Results: With the use of carbon 14-labeled cidofovir in episomal HPV 16-containing keratinocytes, there was a minimal increase in cidofovir incorporation into episomal DNA versus genomic DNA. Cidofovir decreased the copies of episomal HPV 16 in keratinocytes; however, the copies per cell returned to baseline levels once cidofovir was removed. Expression of a viral oncogene (HPV 16 E6) in transformed keratinocytes with episomal HPV 16 was not decreased by cidofovir. Cytotoxicity in head and neck squamous cell carcinoma lines exposed to cidofovir correlated with cell doubling time, and not with HPV status. Also, tonsil keratinocytes transformed with episomal HPV 16 did not exhibit greater cidofovir-mediated toxicity than did telomerase-transformed keratinocytes. Conclusions: These findings suggest that any potential in vivo benefit of cidofovir therapy results from non-viral-specific cell toxicity at the site of application.",
keywords = "Cytotoxicity, Human papillomavirus, Keratinocyte, Recurrent respiratory papillomatosis",
author = "Spanos, {William C.} and Mark El-Deiry and Lee, {John H.}",
year = "2005",
month = "11",
doi = "10.1177/000348940511401106",
language = "English (US)",
volume = "114",
pages = "840--846",
journal = "Annals of Otology, Rhinology and Laryngology",
issn = "0003-4894",
publisher = "Annals Publishing Company",
number = "11",

}

TY - JOUR

T1 - Cidofovir incorporation into human keratinocytes with episomal HPV 16 results in nonselective cytotoxicity

AU - Spanos, William C.

AU - El-Deiry, Mark

AU - Lee, John H.

PY - 2005/11

Y1 - 2005/11

N2 - Objectives: Recurrent respiratory papillomatosis (RRP) is caused by human papillomavirus (HPV). Surgical excision is the mainstay of treatment; however, medical therapy including cidofovir, a cytosine analog, has been investigated. Human papillomavirus does not encode a viral DNA polymerase, which is the known target of cidofovir in cytomegalovirus infections. Methods: In an effort to better understand the usefulness of cidofovir in the treatment of HPV-related disease, we tested cidofovir's ability to inhibit growth, alter gene expression, and inhibit genome replication. Results: With the use of carbon 14-labeled cidofovir in episomal HPV 16-containing keratinocytes, there was a minimal increase in cidofovir incorporation into episomal DNA versus genomic DNA. Cidofovir decreased the copies of episomal HPV 16 in keratinocytes; however, the copies per cell returned to baseline levels once cidofovir was removed. Expression of a viral oncogene (HPV 16 E6) in transformed keratinocytes with episomal HPV 16 was not decreased by cidofovir. Cytotoxicity in head and neck squamous cell carcinoma lines exposed to cidofovir correlated with cell doubling time, and not with HPV status. Also, tonsil keratinocytes transformed with episomal HPV 16 did not exhibit greater cidofovir-mediated toxicity than did telomerase-transformed keratinocytes. Conclusions: These findings suggest that any potential in vivo benefit of cidofovir therapy results from non-viral-specific cell toxicity at the site of application.

AB - Objectives: Recurrent respiratory papillomatosis (RRP) is caused by human papillomavirus (HPV). Surgical excision is the mainstay of treatment; however, medical therapy including cidofovir, a cytosine analog, has been investigated. Human papillomavirus does not encode a viral DNA polymerase, which is the known target of cidofovir in cytomegalovirus infections. Methods: In an effort to better understand the usefulness of cidofovir in the treatment of HPV-related disease, we tested cidofovir's ability to inhibit growth, alter gene expression, and inhibit genome replication. Results: With the use of carbon 14-labeled cidofovir in episomal HPV 16-containing keratinocytes, there was a minimal increase in cidofovir incorporation into episomal DNA versus genomic DNA. Cidofovir decreased the copies of episomal HPV 16 in keratinocytes; however, the copies per cell returned to baseline levels once cidofovir was removed. Expression of a viral oncogene (HPV 16 E6) in transformed keratinocytes with episomal HPV 16 was not decreased by cidofovir. Cytotoxicity in head and neck squamous cell carcinoma lines exposed to cidofovir correlated with cell doubling time, and not with HPV status. Also, tonsil keratinocytes transformed with episomal HPV 16 did not exhibit greater cidofovir-mediated toxicity than did telomerase-transformed keratinocytes. Conclusions: These findings suggest that any potential in vivo benefit of cidofovir therapy results from non-viral-specific cell toxicity at the site of application.

KW - Cytotoxicity

KW - Human papillomavirus

KW - Keratinocyte

KW - Recurrent respiratory papillomatosis

UR - http://www.scopus.com/inward/record.url?scp=32544450329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32544450329&partnerID=8YFLogxK

U2 - 10.1177/000348940511401106

DO - 10.1177/000348940511401106

M3 - Article

C2 - 16363057

AN - SCOPUS:32544450329

VL - 114

SP - 840

EP - 846

JO - Annals of Otology, Rhinology and Laryngology

JF - Annals of Otology, Rhinology and Laryngology

SN - 0003-4894

IS - 11

ER -